PMID: 20647702Jul 22, 2010Paper

Hepatocellular carcinoma

Gan to kagaku ryoho. Cancer & chemotherapy
Shunsuke KondoTakuji Okusaka

Abstract

In two randomized controlled trials (Sorafenib HCC Assessment Randomized Protocol trial and Asian Pacific trial), sorafenib has demonstrated a significantly favorable disease control rate, progression-free survival and overall survival in advanced hepatocellular carcinoma in comparison with placebo. It is presently acknowledged as a standard treatment for advanced hepatocellular carcinoma and is available worldwide. However, the survival benefit and toxicity of sorafenib have been in sufficient, so development of new agents has been more active recently. Development treatment of hepatocellular carcinoma revolves around molecular targeted drugs that target factors associated with tumor growth and angiogenesis. In Japan, clinical trials have involved cytotoxic therapies, but the development of systemic agents for advanced hepatocellular carcinoma has been lacking despite no clear benefits from traditional cytotoxic therapies. S-1, an oral fluoropyrimidine, is currently under evaluation for the treatment of hepatocellular carcinoma in randomized controlled trials. Systemic chemotherapy for hepatocellular carcinoma has been greatly advancing, and further improvements of chemotherapy in hepatocellular carcinoma are expected.

Related Concepts

Related Feeds

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.

Related Papers

Gan to kagaku ryoho. Cancer & chemotherapy
Kohei ShitaraMasaki Munakata
Gan to kagaku ryoho. Cancer & chemotherapy
Satoru Iwasa, Yasuhiro Shimada
International Journal of Clinical Oncology
Narikazu Boku, Gastrointestinal Oncology Study Group of Japan Clinical Oncology Group
© 2021 Meta ULC. All rights reserved